SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

SARS-CoV-2 vaccines have been carefully developed and significantly alleviate the global pandemic. However, a rare but severe complication after vaccination of adenoviral vector vaccines has attracted worldwide attention. It is characterized by thrombosis at unusual sites (often cerebral or abdominal), thrombocytopenia, and the presence of antibodies against platelet factor 4 (PF4), termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Its pathogenesis is similar to that of heparin-induced thrombocytopenia (HIT). VITT progresses rapidly and has a high mortality rate. Clinicians and the public should raise their vigilance to this disease so that accurate and timely treatment is provided.

Automated summary

Vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe complication after adenoviral vector vaccines, has attracted global attention. Its pathogenesis is similar to heparin-induced thrombocytopenia (HIT), and it has a high mortality rate.